



What is the main goal of antineoplastic chemotherapy?

- a. Induce cell proliferation
- b. Inhibit apoptosis
- c. Induce cell death or growth arrest in tumor cells
- d. Promote metastasis
- 2. In the log-kill phenomenon, a given dose of drug destroys a constant fraction of:
  - a. Normal cells
  - b. Host cells
  - c. Cancer cells
  - d. Immune cells
- 3. Neoplasms with a high percentage of proliferation are most susceptible to which type of therapy?
  - a. Cycle-specific
  - b. Non-cycle-specific
  - c. Targeted therapy
  - d. Immunotherapy
- 4. Combination chemotherapy is often more successful because it:
  - a. Targets only specific cell lines
  - b. Causes fewer adverse effects
  - c. Provides additive/synergistic effects and delays resistance
  - d. Requires lower doses of drugs





Which resistance mechanism involves the P-glycoprotein efflux pump?

- a. Inherent resistance
- b. Acquired resistance
- c. Specific resistance
- d. Targeted resistance
- 6. Chemotherapy's selective toxicity is based on:
  - a. Identical metabolic processes in cancer and normal cells
  - b. Differences in DNA structure between cancer and normal cells
  - c. Altered metabolic processes in cancer cells
  - d. Similar immune responses in cancer and normal cells
- 7. Leucovorin is used to rescue normal cells from the effects of which chemotherapy drug?
  - a. Paclitaxel
  - b. Methotrexate
  - c. Cisplatin
  - d. 5-Fluorouracil
- 8. What is the mechanism of action of paclitaxel and docetaxel?
  - a. Inhibit DNA synthesis
  - b. Inhibit microtubule disassembly
  - c. Promote apoptosis





Cisplatin, carboplatin, and oxaliplatin work as alkylating agents by forming:

- a. Phosphodiester bonds
- b. Peptide bonds
- c. Inter- and intrastrand cross-links in DNA
- d. Hydrogen bonds
- 10. Camptothecins, such as irinotecan, primarily inhibit which enzyme?
  - a. Thymidylate synthase
  - b. Topoisomerase I
  - c. Topoisomerase II
  - d. DNA polymerase
- 11. Which drug is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6?
  - a. Nivolumab
  - b. Bevacizumab
  - c. Palbociclib
  - d. Methotrexate
- 12. Immunotherapy involving Nivolumab primarily targets which receptor?
  - a. PD-1
  - b. VEGFR2
  - c. CDK4
  - d. PARP





- 13. The 2018 Nobel Prize in Medicine for Cancer Immunotherapy highlighted advancements in:
  - a. Antimetabolite drugs
  - b. Microtubule inhibitors
  - c. Platinum coordination complexes
  - d. Immunotherapy
- 14. Bevacizumab functions by inhibiting:
  - a. Cyclin-dependent kinases
  - b. Angiogenesis
  - c. Topoisomerase II
  - d. DNA synthesis
- 15. Which drug is used for the treatment of HR-positive and HER2-negative breast cancer?
  - a. Pembrolizumab
  - b. Palbociclib
  - c. Idelalisib
  - d. Ramucirumab
- 16. What is the mechanism of action of topoisomerase I inhibitors like irinotecan?
  - a. Forming inter- and intrastrand cross-links
  - b. Inhibiting microtubule disassembly
  - c. Causing single-stranded breaks in DNA
  - d. Inhibiting thymidylate synthase





- 17. What term is used to describe the situation where a given drug dose destroys a constant fraction of cancer cells?
  - a. First-order kinetics
  - b. Log-kill phenomenon
  - c. Cycle-specific therapy
  - d. Targeted toxicity
- 18. How does leucovorin rescue normal cells from the effects of methotrexate?
  - a. By inhibiting DHFR
  - b. By promoting apoptosis
  - c. By enhancing drug penetration
  - d. By providing additional folate
- 19. What is the primary adverse effect associated with microtubule inhibitors like paclitaxel?
  - a. Nephrotoxicity
  - b. Peripheral neuropathy
  - c. Myelosuppression
  - d. Ototoxicity
- 20. Which category of drugs primarily functions by causing single-stranded breaks in DNA?
  - a. Platinum coordination complexes
  - b. Camptothecins
  - c. Topoisomerase II inhibitors
  - d. Antimetabolites





## (DMJE3

## Answers key:

- 1. c. Induce cell death or growth arrest in tumor cells
- 2. c. Cancer cells
- 3. a. Cycle-specific
- 4. c. Provides additive/synergistic effects and delays resistance
- 5. a. Inherent resistance
- 6. c. Altered metabolic processes in cancer cells
- 7. b. Methotrexate
- 8. b. Inhibit microtubule disassembly
- 9. c. Inter- and intrastrand cross-links in DNA
- 10. b. Topoisomerase I
- 11. c. Palbociclib
- 12. a. PD-1
- 13. d. Immunotherapy
- 14. b. Angiogenesis
- 15. b. Palbociclib
- 16. c. Causing single-stranded breaks in DNA
- 17. b. Log-kill phenomenon
- 18. a. By inhibiting DHFR
- 19. b. Peripheral neuropathy
- 20. b. Camptothecins

